A novel cell-penetrating peptide called Pas2r12 can deliver large proteins like antibodies into the interior of cells just by mixing them together, using a caveolae-mediated entry pathway.
No cross-linking requiredUnlike most cell-penetrating peptide systems, Pas2r12 delivers proteins into cells by simple mixing, eliminating the need for complex chemical conjugation.
What the researchers found
The newly designed cell-penetrating peptide Pas2r12, consisting of a tandem repeat penetration-accelerating sequence (FFLIG-FFLIG) fused to d-dodeca-arginine (r12), significantly enhanced both cellular uptake and cytosolic release of two test proteins: enhanced green fluorescent protein (EGFP) and immunoglobulin G (IgG, an antibody).
A key practical advantage is that Pas2r12 works by simple mixing with cargo proteins — no chemical cross-linking or conjugation is required to form delivery-competent complexes.
Mechanistic studies revealed the delivery process is energy-dependent, requires actin polymerization, and is specifically mediated by caveolae-mediated endocytosis. This was confirmed by inhibition with genistein and methyl-β-cyclodextrin (caveolae inhibitors) and siRNA knockdown of caveolin-1.
Why it matters
Most drugs that target processes inside cells are small molecules because proteins and antibodies are too large to cross cell membranes. A peptide that can deliver these large molecules into cells simply by mixing — without complex chemical modifications — could dramatically simplify intracellular drug delivery and unlock new therapeutic strategies, including intracellular antibody therapy.
How the study worked
Researchers designed and synthesized the Pas2r12 peptide, then tested its ability to deliver fluorescent protein (EGFP) and antibody (IgG) into cells. They used fluorescence microscopy and flow cytometry to measure cellular uptake and cytosolic release. To determine the entry mechanism, they tested energy dependence, actin polymerization inhibitors, caveolae-mediated endocytosis inhibitors (genistein, methyl-β-cyclodextrin), and siRNA against caveolin-1. Experiments were conducted in HEK293 cells.
What this study cannot tell us
The study was conducted in a single cell line (HEK293) and may not generalize to other cell types, particularly primary cells or in vivo tissues. No toxicity or off-target effects were assessed. The efficiency of delivery was not quantified in absolute terms. No in vivo experiments were performed. The stability and pharmacokinetics of Pas2r12 in biological fluids are unknown.
How to read the evidence
This is a proof-of-concept in vitro study demonstrating a novel peptide delivery system in a single cell line. While the mechanistic work is thorough, the translational potential remains to be validated in more complex biological systems.
When this study was published
Published in 2019, this study contributes to the actively evolving field of cell-penetrating peptide research. Subsequent studies may have built on or modified this approach.
The bigger picture
Cell-penetrating peptides have been studied for decades, but efficiently delivering large proteins into the cytosol (not just trapping them in endosomes) remains a major challenge. Pas2r12's ability to achieve cytosolic release through caveolae-mediated endocytosis, without requiring covalent attachment to cargo, represents a meaningful advance in the field. This approach could enable intracellular delivery of therapeutic antibodies, enzymes, and gene-editing proteins.
Questions still open
- Does Pas2r12's delivery efficiency hold up in primary cells and in vivo models where membrane composition varies?
- What is the cytotoxicity profile of Pas2r12 at the concentrations needed for effective protein delivery?
- Could this peptide be used to deliver gene-editing proteins like CRISPR-Cas9 into cells without viral vectors?
Common questions
What are cell-penetrating peptides?
Why is delivering proteins inside cells so difficult?
Read the original research
Oligoarginine-Bearing Tandem Repeat Penetration-Accelerating Sequence Delivers Protein to Cytosol via Caveolae-Mediated Endocytosis.
Biomacromolecules, 20(5), 1849-1859
Citation
Okuda, Akiko; Tahara, Shinya; Hirose, Hisaaki; Takeuchi, Toshihide; Nakase, Ikuhiko; Ono, Atsushi; Takehashi, Masanori; Tanaka, Seigo; Futaki, Shiroh. (2019). Oligoarginine-Bearing Tandem Repeat Penetration-Accelerating Sequence Delivers Protein to Cytosol via Caveolae-Mediated Endocytosis.. Biomacromolecules, 20(5), 1849-1859. https://doi.org/10.1021/acs.biomac.8b01299